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Abstract Polycystin-1 is a putative 460 kDa membrane protein
with a unique structure and is possibly representative of a new
family of proteins. Its structure suggests an involvement in cell
signalling and cell^matrix interactions. The amino acid sequence
of polycystin-1 has to date been predicted from its gene sequence.
This, to our knowledge, is the first report of the isolation and
analysis of polycystin-1 at the protein level using mass spectro-
metry to confirm its predicted structure. The availability of
purified polycystin-1 will allow a new approach to unravelling the
complexity of the cell^cell and cell^matrix interactions of this
large molecule in normal cells and its perturbation in
disease. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
is one of the most common hereditary diseases in humans,
with an incidence rate of about 1:1000 [1]. The predominantly
a¡ected organ in ADPKD is the kidney, where tubule sections
enlarge to form epithelial-lined £uid-¢lled cysts [2]. There are
di¡erent forms of ADPKD caused by mutations in at least
three di¡erent alleles. Approximately 85% of ADPKD cases
are caused by mutations in the PKD1 locus. The rest of the
ADPKD cases are accounted for by mutations in the PKD2
and possibly the PKD3 loci. PKD2 has a late onset and is less
severe so some cases may be undiagnosed [3]. The PKD1
protein product, polycystin-1, is predicted to be a plasma
membrane-associated glycoprotein that contains 4302 amino
acids and has a molecular weight of about 460 kDa [4,5].
Polycystin-1 is predicted to have a unique structure unlike
that of any known protein and may be representative of a
new family of proteins. The extracellular part of polycystin-
1 has two putative leucine-rich repeats £anked by cysteine-rich
domains, a cell-wall and stress-response component domain, a
C-type lectin domain, a low-density lipoprotein domain, 16
‘Ig-like’ PKD repeats and a domain showing high homology
to the sea urchin receptor for egg jelly. The intracellular part
contains several potential phosphorylation sites, a proline-rich
sequence, a heterotrimeric G protein activation sequence and
a coiled-coil domain (reviewed in [6]). It is therefore thought
that polycystin-1 may be involved in cell^cell and cell^matrix
interactions, which are important in renal development but
the nature of its involvement in the pathogenesis of ADPKD
is not currently understood.
Previous studies in our laboratory have established that the
extracellular component laminin has the ability to enhance the
proliferation of tubular epithelial cells in vitro [7] and more
recent studies have demonstrated using a fusion protein that
the polycystin-1 C-type lectin domain binds carbohydrate
structures present in type IV collagen [8]. Polycystin-1 expres-
sion in embryonic development of human tissues was mea-
sured using antibodies prepared against peptide sequences of
the C-terminal region of the molecule and demonstrated that
the staining pattern in the kidney varied with the stage of
development [9].
Polycystin-1 interactions with potential intracellular and
extracellular ligands and their roles in cell signalling have to
date been studied using synthetic peptides and fusion proteins
of particular sections of the molecule rather than the whole
protein [8,10^14]. Furthermore, there are still discrepancies
between the reported distributions of polycystin-1 in the liter-
ature [6]. Some of these discrepancies would be resolved by
the availability of antibodies against the whole molecule. We
therefore set out to isolate polycystin-1 from embryonic kid-
ney ¢broblast cells.
To our knowledge, there have not been any analytical stud-
ies con¢rming the structure or glycosylation of polycystin-1 as
predicted from its gene sequence. Here we describe a method
for the puri¢cation of intact whole polycystin-1 and con¢rm
its identity and predicted structure using mass spectrometry.
2. Materials and methods
2.1. Extraction of soluble proteins from cells
Embryonic kidney epithelial cell monolayers (293) were cultured in
Dulbecco’s modi¢ed essential Eagle’s medium supplemented with 10%
foetal calf serum, 100 U ml31 penicillin, 100 Wg ml31 streptomycin
and 2 mM L-glutamine (Sigma, UK). Con£uent ¢broblast cells (ap-
proximately 1.5U106 cells) were washed with phosphate-bu¡ered sa-
line (PBS), drained and placed on ice. Cells were lysed for 30 min
using lysis bu¡er (100 Wl, 50 mM Tris^HCl, pH 8, 150 mM NaCl,
0.5% DOC, 0.1% SDS, 50 mM NaF, 5 Wg ml31 pepstatin, 25 Wg ml31
aprotinin, 25 Wg ml31 leupeptin, 5 mM EGTA and 1 mM PMSF,
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Sigma, UK) followed by centrifugation at 10 000Ug for 10 min at
4‡C. The supernatant was dialysed against 100 mM NaHCO3 bu¡er,
pH 8.6, prior to mixing with the antibody matrix.
2.2. Generation of polyclonal anti-peptide antiserum
Polyclonal antibodies were generated in rabbits against an antigenic
polypeptide corresponding to amino acid residues 3147^3163 of poly-
cystin-1 [9]. The peptide was coupled to keyhole limpet haemocyanin
for immunisations and to ovalbumin for ELISA analyses, using
m-maleimidobenzoyl-N-dihydroxysuccinimide ester (Sigma, UK) [15].
2.3. Puri¢cation of anti-peptide antibodies
The antigen-a⁄nity gel was prepared by coupling the antigenic
polypeptide to g-aminohexyl-Sepharose 4B using N-Q-maleimido-
butyryloxysuccinimide ester (Sigma, UK) [16]. The immunoglobulin
fraction of the antiserum (10 ml) was ¢rst precipitated with 50%
ammonium sulphate, redissolved in 100 mM sodium phosphate bu¡-
er, pH 7.5 (10 ml), dialysed against 40 mM phosphate bu¡er, pH 8,
and mixed with the antigen-a⁄nity gel (5 ml) for 2 h at room temper-
ature. The gel was transferred to a column, washed with cold TBS,
pH 7.5, and 1 ml fractions were collected on ice until the absorbance
at 280 nm fell to 0.05. After washing with 20 ml of cold distilled
water, bound antibodies were eluted with 100 mM glycine^HCl, pH
2.5. The pH of the eluted fractions was adjusted with 20 Wl of 1 M
Tris^HCl, pH 8. The column fractions were analysed for antibody
activity by direct ELISA using the peptide ovalbumin as the solid
phase antigen. Fractions showing antibody activity were pooled and
dialysed against PBS. Several puri¢cations were performed as de-
scribed and the resulting puri¢ed antibody fractions pooled.
2.4. Preparation of the antibody-a⁄nity gel
The puri¢ed antibodies (20 mg) were coupled to 2 g of CNBr-
activated Sepharose 4B (Sigma, UK) as described in [17]. The anti-
body-a⁄nity gel (5 ml) was ¢rst washed with 500 ml of 100 mM
NaHCO3 containing 200 mM NaCl followed by a wash with gly-
cine^HCl, pH 2.5, and ¢nally washed with PBS, before being stored
in PBS containing 0.1% sodium azide.
2.5. Immunoa⁄nity puri¢cation of polycystin-1
The 293 cell extract was mixed with the antibody-a⁄nity gel over-
night at room temperature. The gel was transferred to a column,
washed and the bound antigen eluted with glycine^HCl, pH 2.5, as
described above for the a⁄nity puri¢cation of the antiserum. Samples
of the column fractions (20 Wl) were diluted in 100 mM NaHCO3 (100
Wl), allowed to adsorb to microtitre plate wells (Griener) and analysed
for polycystin-1 content by direct ELISA. Eluted fractions showing
high polycystin-1 content were pooled, dialysed against PBS and
lyophilised.
2.6. Analysis of the puri¢ed polycystin-1 using SDS^PAGE and
Western blotting
The lyophilised sample was then analysed by SDS^PAGE and
Western blotting. SDS^PAGE in 8% polyacrylamide gels, transfer
to nitrocellulose membranes and silver staining were performed using
standard procedures [18^20]. The membranes were blocked in TBS-T
(0.1% Tween 20) containing 10% milk, incubated with rabbit anti-
polycystin-1 antibodies (1:1000) and goat anti-rabbit horseradish per-
oxidase conjugate (1:20 000), followed by detection using enhanced
chemiluminescence (Amersham Pharmacia Biotech, UK).
2.7. Analysis of the puri¢ed polycystin-1 using mass spectrometry
Following SDS^PAGE, silver staining and Western blotting, the
band corresponding to polycystin-1 was excised from the stained
gel, destained using 30 mM potassium ferricyanide and 100 mM so-
dium thiosulphate and then digested using trypsin as described in [21].
The digested peptide fragments were extracted from the gel using 50%
acetonitrile/0.1% tri£uoroacetic acid, lyophilised, resuspended in 5 Wl
of water and analysed by matrix-assisted laser desorption/ionisation
time-of-£ight mass spectrometry (MALDI-TOF MS) using a LASER-
MAT 2000 mass spectrometer (Thermo Bioanalysis, Hemel Hemp-
stead, UK). The sample was prepared by mixing 0.5 Wl of the tryptic
digest with 0.5 Wl of K-cyano-4-hydroxycinnamic acid directly on the
MALDI target. The monoisotopic mass values of the tryptic digest
fragments were used to search the NCBI non-redundant (nr) database
using the program ProFound and analysis of the tryptic cleavage of
polycystin-1 was performed using the program ProteinInfo (http://
www.proteometrics.com).
3. Results and discussion
Following the extraction of proteins from 293 cells, an anti-
body-a⁄nity matrix was used to prepare a puri¢ed sample of
polycystin-1. Anti-polycystin-1 antibodies were a⁄nity-puri-
¢ed prior to the preparation of the antibody matrix. Compar-
ison of antibody activity in the antiserum before and after
coupling (data not shown) indicated a high coupling e⁄-
ciency. The extracted proteins were mixed with the anti-
body-a⁄nity gel and the bound polycystin-1 was eluted using
low pH (Fig. 1a). Eluted fractions containing high levels of
polycystin-1 were pooled and treated as described above. The
lyophilised sample was analysed by SDS^PAGE and Western
blotting (Fig. 1b,c). A single band of approximately 460 kDa,
corresponding to the predicted molecular weight of polycys-
tin-1, was visualised. Although no other proteins copuri¢ed
with polycystin-1 were detected by SDS^PAGE, the possibil-
ity of the occurrence of undetectable levels of copuri¢ed ma-
terials was not ruled out because of the limitations of SDS^
PAGE and silver staining. Therefore, the visualised band was
analysed by mass spectrometry instead of directly analysing
the lyophilised isolated sample.
Mass spectrometry was used to further characterise the iso-
lated protein because of the inaccurate estimation of the mo-
Fig. 1. The a⁄nity puri¢cation of polycystin-1. a: Analysis of frac-
tions obtained from the anti-polycystin-1 antibody matrix mixed
with cell extract. The arrow indicates the start of elution with gly-
cine^HCl, pH 2.5. Protein content was measured by absorbance at
280 nm and polycystin-1 content by absorbance at 405 nm follow-
ing ELISA. Eluted fractions with high 405 nm readings following
ELISA were pooled, dialysed and lyophilised as described. The
lyophilised material was analysed by (b) SDS^PAGE followed by
(c) Western blotting as described in the text.
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lecular weight due to the limitations of SDS^PAGE especially
for such a high molecular weight protein. The protein band
visualised in the stained gel was excised and subjected to in-gel
tryptic digestion. The tryptic digest was extracted and its com-
ponents detected by MALDI-TOF MS (Table 1 and Fig. 2).
The molecular weights obtained for the fragments were used
to search the NCBInr database using the program ProFound.
The search parameters were as follows: database, NCBInr (4/
17/2001); taxonomy category, Homo sapiens ; protein mass
range, 300^500 kDa; protein pI range, 0^14; search for, single
protein; digest chemistry, trypsin; maximum missed cuts, 1;
modi¢cation, by acrylamide (Cys); charge state, MH and
peptide mass tolerance (MON), þ 0.1 Da. The result of the
search is a single hit which is the human polycystic kidney
disease 1 protein, polycystin-1 (accession numbers AAC37576,
A38971 and NP_000287) with an estimated Z score of 2.43
and sequence coverage of 18% (about 36% if the glycosylation
sites of polycystin-1 are taken into consideration), i.e. the
observed peptides cover 18% of the entire polycystin-1 amino
acid sequence and 36% of the non-glycosylated parts of the
protein. The result obtained is in the 99th percentile, i.e. there
are 1% of random matches that can yield a higher Z score
than this search. Using the program ProteinInfo, the theoret-
ical tryptic cleavage of polycystin-1 as predicted from its gene
Fig. 2. Mass spectrum of the tryptic digest of polycystin-1 obtained by MALDI-TOF MS. The positions of selected tryptic fragments (T) num-
bered from the amino-terminal (obtained by the program ProteinInfo) are shown above the corresponding prominent peaks.
Table 1
Identities of selected tryptic fragments of polycystin-1 observed by MALDI-TOF MS






T3 GCGPCEPPCLCGPAPGAACR (29^48) 1858.6 1858.7 30.1
T49 YSPVVEAGSDMVFR (953^966) 1556.6 1556.7 30.1
T50 WTINDK (967^972) 776.32 776.39 30.07
T64 LTAYVTGNPAHYLFDWTFGDGSSNTTVR (1313^1340) 3090.3 3090.4 30.1
T102 NHVSWAQAQVR (1954^1964) 1295.7 1295.6 +0.1
T110 AFNALGSENR (2042^2051) 1078.4 1078.5 30.1
T127 VALPGVDVSR (2204^2213) 1012.6 1012.5 +0.1
T137 LAAGVEYTFSLTVWK (2330^2344) 1684.7 1684.8 30.1
T212 HLDGDR (3153^3158) 712.31 712.33 30.02
T241 TETLALQR (3507^3514) 931.59 931.52 +0.07
T263 SEELWPWMAHVLLPYVHGNQSSPELGPPR (3719^3747) 3326.5 3326.6 30.1
T266 LQEALYPDPPGPR (3753^3765) 1452.6 1452.7 30.1
T306 LWMGLSK (4138^4144) 834.36 834.45 30.09
T330 VHPSST (4297^4302) 627.29 627.31 30.02
Peptide matches were obtained using the programs ProteinInfo and ProteinFind (www.proteometrics.com). v (Da) is the di¡erence between cal-
culated and observed masses in Da.
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sequence results in 330 tryptic fragments. The fragments we
obtained by the experimental tryptic cleavage range from
tryptic fragment numbers 3 to 330 (Fig. 2), which cover res-
idues 29^4302 of polycystin-1.
Native polycystin-1 is predicted to have about 60 glycosyl-
ation sites (SwissProt accession number P98161). Some of the
products of the tryptic digestion did not match the predicted
masses which may possibly be due to the fact that they con-
tain glycosylation sites and hence di¡er from the computer
predicted masses. Glycosylation residues are thought to be
found within the tryptic fragments T7^T13, T15^T20, T22^
T47, T51^T63 and T68^T99 which are all predicted by the
program ProteinInfo but not observed using the MALDI-
TOF MS. Our results, therefore, do not rule out glycosylation
of the native protein, but rather support glycosylation at the
predicted positions. Furthermore, when the glycosylation sites
are taken into consideration, the observed peptides cover 36%
of the entire amino acid sequence of polycystin-1. The identity
of the puri¢ed product as intact polycystin-1 is therefore con-
¢rmed by three independent pieces of evidence, namely mo-
lecular weight, antigenicity and MALDI-TOF MS.
This, to our knowledge, is the ¢rst report of an analytical
study of polycystin-1 at the protein level, which con¢rms the
molecular weight and structure as predicted from the gene
sequence. The isolation of puri¢ed polycystin-1 will allow
new approaches for the investigation of its cell^cell and cell^
matrix interactions as well as its distribution during develop-
ment and in ADPKD.
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